StockData

HeartSciences vs Sangrix

HSCS and SGRX side by side, both in finance services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HSCS and SGRX compare

Sangrix scores higher on the StockData Score (5 against 3 for HeartSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHSCSSGRX
Size and price
Market cap$9.9M–
Share price$2.06$2.56
Change, 1 year−32.9%−99.6%
Change, 5 years–−100.0%
Beta (5Y)−1.541.40
Employees–1
StockData Score
Total score35 (better)
Valuation score00
Growth score00
Performance score00
Health score35 (better)
Dividend score00
Valuation
P/S2188×–
Profitability
Gross margin60.9%–
Operating margin−209733%–
Net margin−227024%–
Return on equity−1852%–
Return on invested capital–−286%
Financial health
Debt / equity–0.00
Interest coverage−11.8×–
Current ratio0.146.98 (better)
Altman Z-score−42.02–
Piotroski F-score4–
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%–
Ownership
Held by institutions12.8%–
Held by insiders19.2%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.